Ark capitalises on over ten years of research from its founding scientists, Professor John Martin and Mr Stephen Barker of University College London and Professor Seppo Ylä-Herttuala of the AI Virtanen Institute at the University of Kuopio, Finland. Their acknowledged world-renowned clinical and research expertise concentrates in three principal areas;

• A gene vector and expression programme - an established team focused on molecular medicine technology to safely deliver DNA to disease sites within the body see BacV™ – vectors and functional genomics;
  Click here for more information
• Vascular biology and growth factor research programme - an integrated international group of clinicians and scientists focused on understanding diseases of the circulatory system at the molecular level and discovering new treatments;
  Click here for more information
• Scavidin™ - a sophisticated drug targeting platform which can localise and concentrate systemically administered drugs to a desired therapeutic site.
  Click here for more information